In mutant KRAS/TP53-driven tumors, including PDAC, these cellular plasticity programs and tumorigenesis are interconnected; this was established using genetically engineered mouse models (GEMMs) of PDAC, where tumor cells harboring these oncogenic mutation displayed EMT like features at an early stage after tumor initiation (13). This evidence concerns the gene KRAS and neoplasm.